ArticleJournal of medical economicsPublished
Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada
Regional connection
Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source
- Institution
- Merck & Co.
- County
- Montgomery County
Publication record
- Type
- Article
- Venue
- Journal of medical economics
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Chemotherapy, Adjuvant; Markov Chains; Quality-Adjusted Life Years; Middle Aged; Cost-Benefit Analysis; Canada; Antibodies, Monoclonal, Humanized
- PubMed ID
- 40654114
- Added to directory
- Source checked